Statement on Enrollment of First Patient in NYU Langone Health’s Phase 2 Clinical Trial Utilizing ORAVAEXX™

July 22, 2022 – Orcosa is pleased to report the enrollment of the first patient participating in an investigator-initiated Phase 2 clinical trial utilizing ORAVEXX™ (cannabidiol, CBD) at NYU Langone Health Orthopedic Hospital (“NYU Langone”). 

The trial (NCT05020028), an investigator-initiated randomized, double-blind, placebo-controlled clinical trial led by Principal Investigator Dr. Michael J. Alaia of NYU Langone, aims to evaluate if cannabidiol (CBD) delivered utilizing Orcosa’s Rapid Infusion Technology (RITe™) Platform can lessen pain, and improve function and patient satisfaction in cases of knee osteoarthritis over a 12-week period. The trial plans to enroll 100 patients.

RITe™ tablets are fast-acting, easy-to-take tablets engineered to enhance drug absorption. ORAVEXX™ is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain quickly and address the historical issues that CBD research has suffered, including inaccurate dosing, poor bioavailability, and difficult administration. ORAVEXX™ and its matching placebo contain no THC and have been made available to independent investigators seeking to conduct well-designed clinical research in accordance with FDA regulations.